JPMorgan Chase Trims Stake in Incyte Corporation

Institutional investor reduces position in biopharmaceutical company by over 46%

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

JPMorgan Chase & Co. has decreased its stake in Incyte Corporation (NASDAQ:INCY) by 46.2% during the third quarter, according to a recent SEC filing. The fund now owns 447,720 shares of the biopharmaceutical company's stock, down from 832,114 shares previously.

Why it matters

Incyte is a major player in the biopharmaceutical industry, focused on developing novel therapies for cancer, autoimmune disorders, and rare diseases. JPMorgan Chase's reduction in its Incyte position could signal a shift in investor sentiment or portfolio strategy for the financial institution.

The details

According to the filing, JPMorgan Chase sold 384,394 shares of Incyte stock during the third quarter. The firm now owns approximately 0.23% of Incyte's outstanding shares, down from 0.43% previously. The sale comes as Incyte's stock price has fluctuated between $53.56 and $112.29 over the past year.

  • JPMorgan Chase reduced its Incyte position during the 3rd quarter of 2026.

The players

JPMorgan Chase & Co.

A major American multinational investment bank and financial services company.

Incyte Corporation

A biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation.

Got photos? Submit your photos here. ›

The takeaway

JPMorgan Chase's reduction in its Incyte position could signal a shift in investor sentiment towards the biopharmaceutical company, though the reasons behind the move are not entirely clear from the limited information provided. Investors will likely watch to see if other major institutional holders make similar adjustments to their Incyte holdings in the coming quarters.